Tag Archives: hepatitis c

CROI 2017 Hep C Highlights Part II

CROI 2017 Hep C (HCV) HighlightsCROI 2017

The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings.

This blog post is a collection of HIV/HCV highlights that were presented at CROI 2017. Please scroll down and click on the subjects that interest you.

More Interesting CROI 2017 Abstracts about HIV/HCV Coinfection

More information about The Conference on Retroviruses and Opportunistic Infections (CROI), or these and other studies can be found in our blog post CROI 2017 Hep C Highlights Part I or on the conference’s website.

CROI 2017 Hep C Highlights Part I

CROI 2017 Hep C Highlights Part ICROI 2017

The Conference on Retroviruses and Opportunistic Infections (CROI), an annual preeminent HIV research meeting, was held in Seattle, Washington, February 13-16 this year. CROI gathers scientists researching epidemiology and biology of human retroviruses and associated diseases to discuss their findings.

This blog post is a collection of HIV/HCV highlights that were presented. Please scroll down and click on the subjects that interest you.

Interesting Meeting Abstracts about HIV/HCV Coinfection

More information about The Conference on Retroviruses and Opportunistic Infections (CROI), or these and other studies can be found in our blog post CROI 2017 Hep C Highlights Part II or on the conference’s website.

Ontario Drug Benefit Program Funding Hepatitis C Drugs

Ontario Drug Benefit Program Funding Hepatitis C Drugs“The criteria for coverage of hepatitis C treatments is being expanded in a phased approach. Coverage will be further extended to all patients regardless of severity of disease or genotype within the next 12 months.” –Ontario Public Drug Programs

“We look forward to the day that all criteria are lifted and all people living with hep C can access treatment, regardless of disease and genotype.” -Pacific Hepatitis C Network

Reposted from Ontario Public Drug Program Dated February 21, 2017

Effective February 28, 2017, the following hepatitis C drug products will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients for the treatment of hepatitis C.

• Harvoni (ledipasvir/sofosbuvir)
• Sovaldi (sofosbuvir)
• Epclusa (sofosbuvir/velpatasvir)
• Zepatier (elbasvir/grazoprevir)
• Daklinza (daclatasvir)
• Sunvepra (asunaprevir)
• Ibavyr (ribavirin)

The above drugs will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as Limited Use (LU) benefits.

Health care providers are advised to refer to the Formulary for information about the specific reimbursement criteria applicable to each of the funded hepatitis C drugs.

The range of funded hepatitis C drug products will enable funding consideration for patients with most of the common or mixed genotypes in Ontario when the specified criteria are met.

The full details of the LU criteria will be also be posted in the February 2017 monthly Formulary update at:

www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx

For more information, refer to the Frequently Asked Questions (FAQs) for healthcare providers and patients.

Additional Information:
For pharmacies:
Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:
Please call ServiceOntario, Infoline at 1-866- 532- 3161 TTY 1-800-387 -5559. In Toronto, TTY 416- 327 -4282

2016 Highlights of a Local Hepatitis C Advocate

2016 Highlights of a Local Hepatitis C AdvocateHepatitis C advocates are essential to bettering the lives of those living with hep C. As we begin 2017, the Hepatitis C Treatment Information Project wanted to look back and highlight some of the 2016 work of Daryl Luster, one of our hep C advocates.

The following is a collection of 2016 articles, events, and resources that Daryl Luster, hep C advocate and president of PHCN, was a part of:

February 11th, 2016

Daryl Luster wrote an editorial about the price of hepatitis C direct-acting antiviral treatments.

February 25 – 28th
The Canadian Network on Hepatitis C’s 5th Canadian Symposium on Hepatitis C Virus

The Canadian Network on Hepatitis C‘s 5th Canadian Symposium on Hepatitis C Virus took place in Montreal, in 2016. It gathered international experts, including Daryl, together to discuss hep C research into topics such as: treatment, immune response, antiviral resistance, HIV co-infected, and hepatitis C prevention and management.

May 11th
14th Annual Genomics Forum – “Global Impacts of Genomics”

This one-day scientific forum brought researchers and collaborators from all of BC’s life sciences sectors together to share information and discuss opportunities for future collaborations. Daryl took part in the event’s afternoon and panel session about global health and spoke about patients, the nexus of healthcare and research.

April 24th

Daryl Luster wrote an opinion piece that was published by The Vancouver Sun about hepatitis C globally and in BC. It spelt out the importance of testing baby boomers and the neurological and gastrointestinal issues that may be caused by the virus.

July 27th, 2016

Daryl Luster wrote an opinion piece that was published by The Vancouver Sun about hepatitis C globally and in BC. It spelt out the importance of testing baby boomers and the neurological and gastrointestinal issues that may be caused by the virus.

October 18-19th
Action Hepatitis Canada BC Regional Meeting

In our continuing commitment to Action Hepatitis Canada (AHC) and in his role on the steering committee and executive with AHC, Daryl was involved with hosting the meetings in BC. These meetings were part of a cross-Canada series of regional meetings in support of member organizations and the hepatitis community.

October 24th

Daryl Luster wrote an editorial about the newness of hepatitis C direct-acting antiviral treatments and the need to cure whole patients instead of just achieving sustained viral responses.

November 15th

Daryl Luster met with BC NDP MLA Shane Simpson. They spoke about the landscape of hepatitis C in BC, local testing shortfalls, and hep C treatments and cures.

December 1st
World AIDS Day Rally in Vancouver

On this year’s World AIDS Day the hep C and HIV communities stood in solidarity and honoured those they have lost and celebrated the contributions made by community based organizations here, across Canada, and the world. Daryl made a speech urging the Public Health Agency of Canada to rethink the decisions made to grants for HIV and HCV organizations.

Thank you Daryl and all of the hep C advocates who worked so hard in 2016 to speak up for those living with hepatitis C!

The Liver Meeting 2016 by Hep C Treatments

The Liver Meeting 2016 by Hep C TreatmentsThis post lists all of the topics around hep C treatments presented at the Liver Meeting 2016 by treatment as well as their abstract numbers so that one can easily browse the titles and look them up in the meeting’s online abstracts list, Plenary and Parallel Sessions (Abstracts 1–258).

Treatment: Glecaprevir / Pibrentasvir

  • #73 – ENDURANCE-2: Safety and Efficacy of ABT-493/ABT-530 in Hepatitis C Virus Genotype 2-infected Patients without Cirrhosis, a Randomized, Double-Blind, Placebo-Controlled Study
  • #113 – SURVEYOR-II, Part 3: Efficacy and Safety of ABT-493/ ABT-530 in Patients with Hepatitis C Virus Genotype 3 Infection with Prior Treatment Experience and/or Cirrhosis
  • #114 – ENDURANCE-4: Efficacy and Safety of ABT-493/ABT- 530 Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection
  • #253 – ENDURANCE-1: Efficacy and Safety of 8- versus 12-week Treatment with ABT-493/ABT-530 in patients with Chronic HCV Genotype 1 Infection

Treatment: Daclatasvir and Asunaprevir

  • #197 – Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Treatment failure of Interferon-Free Daclatasvir plus Asunaprevir regimen

Treatment: Sovaldi (Sofosbuvir) and Sovaldi Combos (Included Harvoni and Epclusa)

  • #21 – Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir and Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir-Based Antiviral Regimens for Hepatitis C in 17,847 patients in the Veterans Affairs National Healthcare System
  • #23 – Sofosbuvir/Velpatasvir (SOF/VEL)-Based Regimens are Associated with Excellent Efficacy and a Significant Improvement of Patients-Reported Outcomes (PROs) across Patient Populations: From Non-Cirrhotics to Compensated Cirrhotics to Decompensated Cirrhotics
  • #75 – Integrated Analysis of SOF+RBV, LDV/SOF or SOF/VEL for the Treatment of Genotype 4 Chronic HCV Infection
  • #109 – A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/ Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct Acting Antiviral-Experienced Patients with Genotype 1-6 HCV Infection: The POLARIS-4 Study
  • #194 – Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients with Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study
  • #212 – Successful pre- and post liver transplant Sofosbuvir based anti HCV treatment in persons living with HIV infection
  • #213 – Efficacy and safety treating the recurrent hepatitis C post-liver transplantation with simeprevir and sofosbuvir: The Spanish experience (SETH)

Treatment: Zepatier (Grazoprevir/Elbasvir)

  • #74 – C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment- naïve and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks
  • #76 – Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naive Subjects with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized Multinational Clinical Trial
  • #110 – Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2)
  • #112 – High Sustained Virologic Response (SVR) Rates in Patients with Chronic HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/MK-8408 Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of C-CREST-1 & 2)
  • #193 – Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE)

Treatment: Elbasvir

  • #195 – Distinct Evolutionary Pathways of NS5A Inhibitor Resistance in Patients With Genotype 1a Versus 1b Infection During Monotherapy With MK-8742 (Elbasvir)

Treatment: RG-101

  • #111 – RG-101 in Combination with 4 Weeks of Oral Direct Acting Antiviral Therapy Achieves High SVR Rates in Treatment Naïve Genotype 1 and 4 Chronic Hepatitis C Patients

The Liver Meeting 2016

The Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, was held November 11th – 15th. Last year’s meeting drew more than 9,500 international hepatologists and hepatology health professionals to San Francisco to discuss the latest treatments and research for liver diseases. This year, Boston, Massachusetts, hosted the meeting and, as always, it was exciting.

More information about The Liver Meeting 2016 or these and other studies can be found in our blog post The Liver Meeting 2016 Hep C Abstract Highlights (Part2) or on the American Association for the Study of Liver Diseases (AASLD)’s website.

The 2016 Liver Meeting by 2 Attending Blog Writers

2016 Liver Meeting via Attending Blog WritersAttending the Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, this year are not only researchers and physicians, but also a number of different blog writers.  The below is some of what these writers have been hearing and writing about.

2016 Liver Meeting Highlights being Written about by Two Attending Blog Writers

By Lucinda K. Porter, RN

Summary: A general description of the Liver Meeting 2016. “There were quite a few presentations on fatty liver diseases (FLD) such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). FLDs are rapidly overtaking hepatitis C as the most prevalent liver threat.”

Summary: A post about two of Porter’s favorite conference posters, Abstract #868 Safety and Tolerability of Direct Acting Antiviral Agents (DAAs) Used in Usual Clinical Practice: HCV-TARGET International Consortium, by Michael W. Fried, et al., and Abstract #911 Alcohol Use and Hepatitis C Virus Treatment Outcomes Among 15,151 Patients Receiving Direct Antiviral Agents, by Judith Tsui, et al. Editorial comments included.

Summary: A post highlighting Abstract # LB-15 Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration(SURVEYOR-II, Part 4), by Tarek Hassanein, et al., and Abstract #831 Hepatitis C (HCV) Virologic Outcomes in Veterans Taking Ledipasvir/Sofosbuvir With Concomitant Acid Suppressing Medication – Austin Chan, et al. Editorial comments included.

By HIVandHepatitis.com

Summary: The hep C treatment Zepatier (grazoprevir/elbasvir) and Sovaldi (sofosbuvir) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hep C genotype 3 and liver cirrhosis, matching rates seen in easier-to-treat patient groups.

Summary: Direct-acting antiviral treatments have real-world rates similarly found in clinical trials, without major differences between treatment regimens.

Summary: Being cured of hepatitis C with direct-acting antiviral treatment doesn’t increase one’s risk of developing hepatocellular carcinoma (HCC) and may reduce it. (Canadian Study)

More information about the Liver Meeting or information about these and other studies can be found in our blog post The Liver Meeting 2016 Hep C Abstract Highlights (Part1), on the American Association for the Study of Liver Diseases (AASLD)’s website, or by clicking the links listed above.

To treat or to wait? That may be the question with hep C treatment.

To treat or to wait? That may be the question with hep C treatment.To treat or to wait? Only you and your doctor–and possibly BC PharmaCare–can decide whether you should begin hepatitis C treatment now or wait. However, there are resources that may be able to help you answer that question or to think about the factors one may want to think about when considering treatment for hepatitis C. For example, current state of health, virus genotype, work and family circumstances, as well as financial considerations, may all be factors that can influence if, and when, a person decides to try to treat their hepatitis C.

Basic Facts about Hep C Treatment to Consider

Historically, treatment for hepatitis C has been difficult and long – up to a year. However, even now, when newer treatments boost shorter treatment times (8 – 24 weeks) and much less side effects, patients may still face treatment difficulties. A few patients still find that the new treatments are impossible to complete health-wise or find that treatment is too disruptive, given their current life circumstance or health situation. Therefore, patients still decide, or are advised by their healthcare providers, to delay treatment, even when new treatments are available.

Also–and this one is a big one–one should be aware that even newer, possibly better, hep C treatments are on their way.

Resources Weighing the Risks and Benefits of Treating or Waiting to Treat Hepatitis C

Resources Designed to Help You Talk to Your Doctor

Peer Supports

There are a number of support groups and hotlines available to support you and to answer your questions. Going online is a great way to find local groups and connect to communities through social media, especially on Facebook.

However, one of your best resource when considering whether to treat on not to treat will always be your own healthcare provider or a healthcare provider. They can talk to you about your different health concerns and weigh in on whether they think treatment is right for you while knowing you and your medical history.

To treat or not to treat? That is still a question asked and still one that should be asked.

Please contact us at hepctip@pacifichepc.org or check out our Considering Treatment page for more information.

The Liver Meeting 2016 Hep C Abstract Highlights (Part2)

Liver Meeting 2016 Hep C Abstract HighlightsThe Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, will be held November 11th to the 15th. Last year’s meeting drew more than 9,500 international hepatologists and hepatology health professionals to San Francisco to discuss the latest treatments and research for liver diseases. This year, Boston, Massachusetts, will be hosting the meeting and, as always, the meeting promises to be exciting.

Hep C Abstract Highlights to be Presented at The Liver Meeting 2016 (Part 2)

  • Eight weeks treatment duration with Ledipasvir/Sofosbuvir (LDV/SOF) is effective for appropriately selected patients with genotype 1 Hepatitis C virus (HCV) infection: an analysis of multiple real world cohorts totaling >6,500 patients, by Vinay Sundaram, et al. (LB-16)

Summary: Current studies are limited by lack of uniform data regarding fibrosis stage or risk factors for relapse when it comes to 8 weeks of treatments with LDV/SOF (Harvoni).  Looking at past records, the research team determined the effectiveness of 8 weeks of treatment (SVR rates >95% in selected patients), examined variables associated with relapse, and compared the efficacy of 8 weeks with 12 weeks of therapy.  The results were in the 90s for those >65 years, HIV co-infected, Caucasian and African-American, fibrosis stages of 0-3, and genotype 1a and 1b.

  • Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A Review of Spontaneous Post-Marketing Cases, by Susan J. Bersoff-Matcha, et al. (LB-17)

Summary: There have been recent published cases of hepatitis B virus reactivation (HBV-R) in patients with HCV/HBV coinfection. Before DAAs, this is often seen with immunosuppression, although, DAAs don’t suppress immune response. Therefore, the purpose of this evaluation was to assess spontaneous reports of HBV-R with DAA treatment. The conclusion was that it does happen and that further study is needed into the reasons for it and how to stop it from occurring.

  • Retreatment with sofosbuvir + grazoprevir + elbasvir + ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir + ledipasvir or + daclatasvir or + simeprevir regimen (ANRS HC34 REVENGE study), by Victor de Ledinghen, et al. (LB-18)

Summary: The best treatment regimen for such patients who have already tried but failed treatment is still unknown. This study evaluated sofosbuvir + grazoprevir + elbasvir + ribavirin, taken for 16 weeks vs 24 wks in patients with NS5A or NS3 resistance-associated substitutions (RASs), when treatment failed. SVR4 was achieved by 16/17 patients. The finding suggested that “…retreating patients who failed a DAA-based regimen with NS5A/NS3 RASs with the combination of SOF + GZR + EBV + RBV for 16 weeks is efficacious and represent an interesting option. Safety will need to be monitored cautiously for this combination.”

  • Reduction in Liver Transplant Wait-Listing in the Era of Direct Acting Anti-Viral Therapy, by Jennifer A. Flemming, et al. (LB-23)

Summary: The study analyzed trends in liver transplant wait-lists to explore the potential impact of effective medical therapy on wait-list registration. The findings found that wait-lists have reminded the same for those with hep B but the number of those waiting for livers due to hep C has decreased by over 30% in the era of DAA therapy. Further reductions of wait-lists may result from increased testing, linkage to care, and access to DAA treatment.

More information about this meeting or these and other studies can be found in our blog post The Liver Meeting 2016 Hep C Abstract Highlights (Part1) or on the American Association for the Study of Liver Diseases (AASLD)’s website.

The Liver Meeting 2016 Hep C Abstract Highlights (Part1)

The Liver Meeting 2016 Hep C Abstract Highlights (Part1)The Liver Meeting 2016, the American Association for the Study of Liver Diseases (AASLD)‘s 67th annual meeting, will be held November 11th to the 15th. Last year’s meeting drew more than 9,500 international hepatologists and hepatology health professionals to San Francisco to discuss the latest treatments and research for liver diseases. This year, Boston, Massachusetts, will be hosting the meeting and, as always, the meeting promises to be exciting.

Hepatitis C Treatment Topics to be Presented at The Liver Meeting 2016 (Part I)

  • GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial, by Rohit Loomba, et al. (LB-3)

Summary: “ASK1 is a serine threonine kinase that promotes hepatic inflammation and fibrosis in the setting of oxidative stress. Our aim was to describe the preliminary efficacy of GS-4997, a selective inhibitor of ASK1, alone or in combination with simtuzumab (SIM), in patients with NASH and moderate to severe liver fibrosis.” (Loomba, et al.) This study found that a 24-week course of GS-4997 reduced liver fibrosis and lowered hepatic stiffness in patients with NASH and moderate to severe fibrosis.

  • EXPEDITION-IV: Safety and Efficacy of GLE/PIB in Adults with renal impairment and Chronic Hepatitis C Virus Genotype 1 – 6 Infection, by Edward J. Gane, et al. (LB-11)

Summary: Currently, severe renal impairment still limits treatment options for those with hepatitis C. This study showed that a fixed dose of GLE/PIB (glecaprevir/pibrentasvir) taken once  a day for 12 weeks was well tolerated by patients with severe renal impairment, without any serious side effects. 99% of patients achieving SVR4, hep C cure.

  • A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study, by Ira M. Jacobson, et al. (LB-12)

Summary: This study compared treatment with sofosbuvir/velpatasvir/voxilaprevir for 8 weeks with treatment with sofosbuvir/velpatasvir (brandname Epclusa) for 12 weeks in patients with genotype 1-6 hepatitis C, who had or didn’t have liver cirrhosis, and who hadn’t previously been treated with a direct-acting antiviral agent (DAA). The most common side effect were headache, fatigue, diarrhea and nausea while taking SOF/VEL, and diarrhea and nausea while taking SOF/VEL/VOX.
Clinical Trial Results:

SVR4 % Total GT1 GT2 GT3 GT4 GT5 GT6 Other
SOF/VEL/VOX 8 Weeks 96 (482/ 501) 95 (221/ 233) 97 (61/ 63) 100 (92/ 92) 94 (17/ 18) 94 100 (30/ 30) 100 (2/2)
SOF/VEL 12 Weeks 98 (432/ 440) 99 (229/ 232) 100 (53/ 53) 97 (86/ 89) 96 (55/ 57) 100 (9/9)
  • A Novel Single Daily Fixed Dose Combination of Sofosbuvir 400 mg + Ribavirin 1000mg + EGCG400 mg is Superior to the Standard of Care as an Anti-Viral and Safer Causing less Hemolysis in Patients with Chronic Hepatitis C, by Gamal Shiha, et al. (LB-14)

Summary: Sofosbuvir has improved hep C treatments and outcomes, however, it is extremely costly and there is a risk of selecting viral escape mutants so a new combination, focusing on other steps in the infection process, may be better. Therefore, EHCV (Catvira) formulation composed of sofosbuvir / ribavirin / epigallocatechin gallate 400 mg (EGCG) is being developed. SVR 12 and SVR 24 for EHCV (Catvira) show results similar to those reached by the current standard of care, but with a much faster rate of viral load decline, for both treatment experienced and treatment naive genotype 4 hep C patients.

  • Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration (SURVEYOR-II, Part 4), by Tarek I. Hassanein, et al. (LB-15)

Summary: The hepatitis C virus genotypes (GTs) 2, 4, 5 and 6 are everywhere and together make up approximately 23% of global hep C infections. With these genotypes being so widespread, it is important to have treatments and improving treatments for them as well. In previous phase 2 studies, SVR12 rates of 98% and 100% were achieved following treatment with GLE/PIB for 8 weeks in GT2 infected patients or 12 weeks in GT 4-6 infected patients. This study, SURVEYOR-II Part 4, looked at the safety and efficacy of 8-week GLE/PIB treatment in patients with GT4-6 infection, and a larger group of GT2-infected patients.  The study’s results were as follows:

SVR4 % Total GT2 GT4 GT5 GT6
GLE/PIB 8 Weeks 98 97 (141/145) 98 (45/46) 100 (2/2) 100 (10/10)

Lastly, more information about The Liver Meeting 2016 or these and other studies can be found in our blog post The Liver Meeting 2016 Hep C Abstract Highlights (Part2) or on the American Association for the Study of Liver Diseases (AASLD)’s website.

The 5th International Symposium on Hepatitis Care in Substance Users 2

Hepatitis Care in Substance UsersThe 5th International Symposium on Hepatitis Care in Substance Users (#INHSU2016) began in Oslo, Norway, today and will run until Friday. This international conference is the biggest symposium of its kind that focuses on the management of hepatitis among substance users. It is organized by the International Network for Hepatitis in Substance Users (INHSU) and attracts health professionals, researchers, community organizations, substance users, and policy makers yearly. This year, the international symposium’s focus is on epidemiology and public health, treatment and care, and access to care. The following blog post highlights just some of the information that will be presented.

Hepatitis C Treatment Topics Presented at the 5th International Symposium on Hepatitis Care in Substance Users (Part 2)

Summary: This study aimed to provide more information about reinfection rates after successfully completing hep C (HCV) treatment (elbasvir, grazoprevir, and OAT). The study concluded that “follow-up is required to determine the natural course of HCV reinfection in the setting of interferon-free HCV treatment and the impact of viral persistence following reinfection on long-term response rates in this population.” (Dalgard)

Summary: This study demonstrates that outreach screening and hep C treatment within a Drug Treatment Unit is feasible and effective. It also saves money over time.

Summary: This study demonstrates that People Who Inject Drugs (PWID) can successfully complete treatment while continuing to use drugs.

Summary: This study, and the one below it, demonstrates the importance of care and support for those who have taken hep C treatment and were cured. The study suggests that support shouldn’t end with a hep C virus cure.

Summary: This study, and the one listed above, demonstrates the importance of care and support for those who have taken hep C treatment and were cured. The study suggests that support shouldn’t end with a hep C virus cure.

Summary: Yes, however, access to treatment that can cure patients, even hard to treat patients, must increase. The study assessed 509 patients. Fifty-nine of these patients were “…assessed as non-treatable. Main reasons being instability and lost to follow up.” (Ovrehus)

Summary: There are only  a few trials that look at how well patients are able to take their hep C treatment correctly. This trial is one of them.  It enrolled 59 trial participants with different degrees of drug use and found that “…despite high rates of substance use, a community-based model of HCV treatment can support positive HCV treatment outcomes.” (Mason)

Additional information about the abstracts listed above or other abstracts that were part of the 5th International Symposium on Hepatitis Care in Substance Users can be found in the symposium’s programme or in part 1 of this blog post.